Search hospitals > Michigan > Flint
Hurley Medical Center
Claim this profileFlint, Michigan 48503
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Leukemia
Conducts research for Recurrence
657 reported clinical trials
7 medical researchers
Summary
Hurley Medical Center is a medical facility located in Flint, Michigan. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Leukemia, Recurrence and other specialties. Hurley Medical Center is involved with conducting 657 clinical trials across 719 conditions. There are 7 research doctors associated with this hospital, such as Tareq Al Baghdadi, Christopher M. Reynolds, MD, Philip J. Stella, and Elie G. Dib.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderHER2 negative
ER positive
Stage IV
Top PIs
Tareq Al BaghdadiSaint Joseph Mercy Hospital7 years of reported clinical research
Expert in Cancer
Expert in Tumors
70 reported clinical trials
127 drugs studied
Christopher M. Reynolds, MDSaint Joseph Mercy Hospital4 years of reported clinical research
Expert in Cancer
Studies Lung Cancer
45 reported clinical trials
99 drugs studied
Philip J. StellaSaint Joseph Mercy Hospital4 years of reported clinical research
Expert in Lung Cancer
Expert in Non-Small Cell Lung Cancer
38 reported clinical trials
89 drugs studied
Elie G. DibSaint Joseph Mercy Hospital4 years of reported clinical research
Expert in Cancer
Studies Breast Cancer
34 reported clinical trials
94 drugs studied
Clinical Trials running at Hurley Medical Center
Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Cancer
Gastric Cancer
Esophageal Cancer
Gastroesophageal Junction Adenocarcinoma
Esophageal Adenocarcinoma
Bladder Cancer
Multiple Myeloma
Radiation and HER2-Targeted Therapy
for Breast Cancer
This Phase III trial compares the recurrence-free interval (RFI) among patients with early-stage, low risk HER2+ breast cancer who undergo breast conserving surgery and receive HER2-directed therapy, and are randomized to not receive adjuvant breast radiotherapy versus those who are randomized to receive adjuvant radiotherapy per the standard of care.
Recruiting2 awards Phase 315 criteria
Chemotherapy + Hormone Therapy
for Breast Cancer
This trial is testing if adding additional cancer-fighting drugs to treatments that stop certain body functions is better than just using the treatments that stop those functions alone. It targets younger women with early-stage breast cancer who have a higher risk of dying from the disease. The treatment works by stopping certain body functions and using drugs to kill cancer cells.
Recruiting2 awards Phase 319 criteria
Shorter Chemo-Immunotherapy Without Anthracyclines
for Breast Cancer
This phase III trial compares the effects of shorter chemotherapy (chemo)-immunotherapy without anthracyclines to usual chemo-immunotherapy for the treatment of early-stage triple negative breast cancer. Paclitaxel is in a class of medications called anti-microtubule agents. It stops cancer cells from growing and dividing and may kill them. Carboplatin is in a class of medications known as platinum-containing compounds. It works in a way similar to the anticancer drug cisplatin, but may be better tolerated than cisplatin. Carboplatin works by killing, stopping or slowing the growth of cancer cells. Cyclophosphamide is in a class of medications called alkylating agents. It works by damaging the cell's deoxyribonucleic acid (DNA) and may kill cancer cells. It may also lower the body's immune response. Docetaxel is in a class of medications called taxanes. It stops cancer cells from growing and dividing and may kill them. Doxorubicin is an anthracycline chemotherapy drug that damages DNA and may kill cancer cells. Pembrolizumab may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Shorter treatment without anthracycline chemotherapy may work the same as the usual anthracycline chemotherapy treatment for early-stage triple negative breast cancer.
Recruiting2 awards Phase 347 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Hurley Medical Center?
Hurley Medical Center is a medical facility located in Flint, Michigan. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Leukemia, Recurrence and other specialties. Hurley Medical Center is involved with conducting 657 clinical trials across 719 conditions. There are 7 research doctors associated with this hospital, such as Tareq Al Baghdadi, Christopher M. Reynolds, MD, Philip J. Stella, and Elie G. Dib.
Where is Hurley Medical Center located?
**Hurley Medical Center Directions:**
- **Address:** 1 Hurley Plaza, Flint, MI.
- **Driving:** Take I-475 N to exit 4 for Saginaw St, then head west on Saginaw St.
- **Alternative:** For real-time traffic updates, consider using Waze.
Who should I call to ask about financial aid or insurance network?
For financial assistance at Hurley Medical Center, call the Financial Assistance office at (810) 262-9255. For inquiries about your stay, contact the Patient Relations office at (810) 262-9220.
What insurance does Hurley Medical Center accept?
Hurley Medical Center accepts most U.S. insurances. They advise verifying coverage for Bariatric Surgery or Morbid Obesity with your insurance carrier. They offer Advanced Neuropsychology and Pediatric Psychology Services as an approved provider for many health insurance plans and provide a discount program for uninsured individuals requiring financial support.
What awards or recognition has Hurley Medical Center received?
Hurley Medical Center, located in Flint, Michigan, is renowned for its exceptional patient care and holds accreditation from The Joint Commission. The hospital boasts a range of distinguished programs including a Level I Trauma Center, Level III Neonatal Intensive Care Unit, and a Nationally-accredited Breast Cancer Program, among others. It is also committed to community health through initiatives targeting childhood obesity, diabetes education, asthma management, and improving food access.